H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Autolus Therapeutics (AUTL) today and set a price target of $24.00. The company’s shares closed last Monday at $9.95, close to its 52-week low of $9.40.
According to TipRanks.com, Chattopadhyay is a 4-star analyst with an average return of 4.3% and a 44.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences, and Sarepta Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $25.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.84 and a one-year low of $9.40. Currently, Autolus Therapeutics has an average volume of 158.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.